Danish pharmaceutical company Genmab reported increased sales in the first quarter of 2025 compared with the same period last year. Operating profit increased.

Net sales rose 18.6 percent to $715 million (603).

Operating profit was $188 million (116). The operating margin was 26.3% (19.2).

Profit after tax was $195 million (192).

Genmab reiterates its guidance for the full year 2025.

Genmab, MUSDQ1-2025 Q1 Change
Net sales 71 603 18
Operating 188 116 62.1
Operating margin 26 19
Net profit 195 192 1
Consensus data from Bloomberg